Repository logo
 
Publication

Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

2024-01-18Journal article Open access
Simple item page
dc.contributor.authorAntunes, Liliana
dc.contributor.authorMazagatos, Clara
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorGómez, Verónica
dc.contributor.authorBorg, Maria-Louise
dc.contributor.authorPetrović, Goranka
dc.contributor.authorDuffy, Róisín
dc.contributor.authorDufrasne, François E
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorLazar, Mihaela
dc.contributor.authorJancoriene, Ligita
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorHusa, Petr
dc.contributor.authorHoward, Jennifer
dc.contributor.authorMelo, Aryse
dc.contributor.authorPozo, Francisco
dc.contributor.authorPérez-Gimeno, Gloria
dc.contributor.authorCastilla, Jesús
dc.contributor.authorMachado, Ausenda
dc.contributor.authorDžiugytė, Aušra
dc.contributor.authorKarabuva, Svjetlana
dc.contributor.authorFitzgerald, Margaret
dc.contributor.authorFierens, Sébastien
dc.contributor.authorTolksdorf, Kristin
dc.contributor.authorPopovici, Silvia-Odette
dc.contributor.authorMickienė, Auksė
dc.contributor.authorTúri, Gergő
dc.contributor.authorSoučková, Lenka
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorRose, Angela MC
dc.contributor.authoron behalf of the European Hospital Vaccine Effectiveness Group
dc.date.accessioned2024-01-22T10:59:07Z
dc.date.available2024-01-22T10:59:07Z
dc.date.issued2024-01-18
dc.descriptionMembers of the European Hospital Vaccine Effectiveness Group: Portugal: Ana Paula Rodrigues, Débora Pereira, Susana Costa Maia e Silva, Paula Pinto, Cristina Bárbara, António Pais de Lacerda, Raquel Guiomar and Camila Henriques.pt_PT
dc.description.abstractThe European Medicines Agency (EMA) authorised four adapted bivalent mRNA COVID-19 vaccines for use against COVID-19 in September/October 2022: Comirnaty (BNT162b2; Pfizer-BioNTech) and Spikevax (mRNA-1273; Moderna) Original/Omicron BA.1 and Original/Omicron BA.4–5 [1]. During autumn 2022, all European Union/European Economic Area (EU/EEA) countries had vaccination campaigns in place to administer a booster dose, with several countries using the adapted bivalent vaccines [2]. The Omicron-descendent XBB lineage and XBB.1.5 sub-lineage became variants of interest in March 2023 [3]. We estimated the effectiveness of the COVID-19 bivalent vaccines against hospitalisation with PCR-confirmed SARS-CoV-2 infection among patients aged ≥ 60 years with severe acute respiratory infection (SARI) during the XBB lineage-predominant period.pt_PT
dc.description.sponsorshipThe ‘Vaccine Effectiveness, Burden and Impact Studies studies’ (VEBIS) is a project of the European Centre for Disease Prevention and Control (ECDC) run under the framework con tract No. ECDC/2021/016.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationEuro Surveill. 2024 Jan;29(3):2300708. doi: 10.2807/1560-7917.ES.2024.29.3.2300708pt_PT
dc.identifier.doi10.2807/1560-7917.ES.2024.29.3.2300708pt_PT
dc.identifier.issn1025-496X
dc.identifier.urihttp://hdl.handle.net/10400.18/8934
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherEuropean Centre for Disease Prevention and Controlpt_PT
dc.relation.publisherversionhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectCOVID-19 Bivalent Vaccinespt_PT
dc.subjectHospitalisationpt_PT
dc.subjectSARIpt_PT
dc.subjectXBBpt_PT
dc.subjectVEBIS-LOT 1pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectVaccine Effectivenesspt_PT
dc.subjectEuropept_PT
dc.subjectVacinapt_PT
dc.subjectEfetividadept_PT
dc.subjectObservação e vigilânciapt_PT
dc.subjectInfecções Respiratóriaspt_PT
dc.subjectCuidados de Saúdept_PT
dc.titleEffectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue3pt_PT
oaire.citation.startPage2300708pt_PT
oaire.citation.titleEurosurveillancept_PT
oaire.citation.volume29pt_PT
person.familyNamedo Carmo Cerdeira Antunes
person.familyNameGOMEZ TEIXEIRA PINTO
person.familyNameMachado
person.givenNameLiliana
person.givenNameVERÓNICA DEL PILAR
person.givenNameAusenda
person.identifier.ciencia-idE51A-FB28-9B01
person.identifier.ciencia-idFA1B-D68F-2611
person.identifier.ciencia-id1217-6076-5D88
person.identifier.orcid0000-0003-0453-5304
person.identifier.orcid0000-0003-0485-0005
person.identifier.orcid0000-0002-1849-1499
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication3241060c-e155-4c58-9c68-a6afba0e48be
relation.isAuthorOfPublicationeae04cda-2c73-437b-8666-6593d03aa34d
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublication.latestForDiscoveryeae04cda-2c73-437b-8666-6593d03aa34d

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Effectiveness of the adapted bivalent mRNA COVID-19 XBB.pdf
Size:
564.14 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais